A Longitudinal Retrospective Claims Analysis of Healthcare Costs Incurred by Uterine Fibroids Patients

A. M. Soliman,M. Fuldeore,H. Yang,E. X. Du,E. Q. Wu,C. Winkel
DOI: https://doi.org/10.1016/j.fertnstert.2014.07.969
IF: 6.7
2014-01-01
Fertility and Sterility
Abstract:Since uterine fibroids (UF) impose a high economic and societal burden, but UF diagnosis is often delayed and economic information on this pre-diagnosis period is scarce, here we compared healthcare costs for 5 years before and 5 after UF diagnosis with those in women without UF. Case-control study, using 2000-2010 Truven Health MarketScan data. Patients aged 18-45 years with an UF diagnosis (International Classification of Diseases code 218.xx) were matched 1:1 to women without UF (controls) by age, region, and insurance type. For each matched pair, the UF case's first recorded UF diagnosis date was assigned as the index date. At least 1 year of continuous eligibility in a health plan was required for all subjects. Individuals' ages and comorbidities during the year before the index date were summarized. Annual healthcare costs (in 2010 US dollars) during the 5 years pre- and post-index were compared between UF patients and controls using Wilcoxon signed-rank tests. Among the 84,954 matched pairs identified, the mean age at index date was 39.3 years. Inflammatory disease of gynecological organs (12.5%), urinary tract infection (11.0%), depression (6.4%), infertility (3.2%) and endometriosis (3.1%) were the most common comorbidities among UF patients. For three years prior to the index date, average annual total healthcare costs (medical plus pharmacy costs) were significantly higher for UF patients than for controls: ranging, across the years, from $3,381-$4,217 for UF patients versus $3,237-$3,546 for controls (all p<0.05), producing annual cost differences of $144-$671. In the first year after the index date, UF patients incurred an average of $9,933 in total healthcare costs, compared to only $3,802 for control patients (p<0.05). In the subsequent four years, UF patients' total costs exceeded those of the controls by $1,443, $1,560, $1,136, and $920, respectively (all p<0.05). Both the medical and pharmaceutical costs components exhibited the same trends as the total cost estimates for UF patients. Patients with UF incurred significantly higher healthcare costs than those without UF, both pre- and post-diagnosis; the costs associated with UF were highest in the years immediately following diagnosis. UF disease imposes a significant economic burden on women aged 18-45 years living in the US.
What problem does this paper attempt to address?